RxDoctor Payments Data

Chadd Eaglin, MD

Psychiatry · Jacksonville Beach, FLNPI 1750599833

Payments from drug & device makers

$490,027in general payments, 2019–2025

Across 1,284 payments — averaging $381.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$307K
  • Axsome Therapeutics, Inc.$174K
  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$1K
  • Vanda Pharmaceuticals Inc.$1K
  • plus $5K from 20 others

What the payments were for

  • Consulting fees$41,4008%
  • Speaking & faculty fees$379,24577%
  • Travel & lodging$44,6759%
  • Food & beverage$24,5965%
  • Education$1100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$490,027 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$87,918
Medicare patients
23
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl54$76,624
AuvelityDextromethorphan Hbr/Bupropion25$27,442
QuviviqDaridorexant Hcl11$4,868
VyvanseLisdexamfetamine Dimesylate11$3,800
AdderallDextroamphetamine/Amphetamine12$3,790
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine116$3,546
Duloxetine Hcl31$1,851
Alprazolam160$1,778
Aripiprazole33$1,234
Bupropion XlBupropion Hcl25$1,138
Vilazodone Hcl11$857
Clonazepam87$780
Nortriptyline Hcl13$665
Quetiapine Fumarate21$643
Escitalopram Oxalate38$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$306,897$76,62454 claims
Axsome Therapeutics, Inc.Auvelity$173,524$27,44225 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Adderall$621$7,59023 claims
Idorsia Pharmaceuticals US IncQuviviq$351$4,86811 claims
Almatica Pharma LLCSertraline Hcl$461$22433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Jacksonville Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →